Perphenazine is one of the older antipsychotics most psychiatrists today have only read about. It was developed in the 1950s, marketed as Trilafon, and largely fell out of favour as second-generation drugs arrived in the 1990s. It then had an unexpected second life when the landmark CATIE trial compared it head-to-head with several newer agents and found it broadly comparable in real-world effectiveness. That result changed how many clinicians think about the older drugs — and it makes understanding perphenazine's side effect profile worthwhile.
Perphenazine is a mid-potency first-generation antipsychotic with a moderate burden of movement side effects, mild metabolic effects, and an effectiveness profile that surprised many clinicians in the CATIE trial.
Where it sits on the first-generation spectrum
First-generation antipsychotics are usually grouped by potency. High-potency drugs (haloperidol, fluphenazine) cause more EPS but less sedation and metabolic effects. Low-potency drugs (chlorpromazine, thioridazine) cause less EPS but more sedation, anticholinergic effects, and orthostasis. Perphenazine sits squarely in the middle, which gives it a generally well-balanced profile that many patients find tolerable.
What CATIE actually showed
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, funded by NIMH and published in the New England Journal of Medicine in 2005, compared perphenazine with olanzapine, quetiapine, risperidone, and ziprasidone in nearly 1,500 patients with chronic schizophrenia. The primary outcome was time to discontinuation for any reason. Olanzapine performed best, but perphenazine was not statistically different from quetiapine, risperidone, or ziprasidone — and was substantially less expensive. EPS rates were not dramatically higher with perphenazine than with the second-generation comparators in this trial. The CATIE result became one of the central reasons perphenazine remains in use today.
Movement side effects
EPS
Perphenazine causes more EPS than most second-generation drugs but considerably less than haloperidol or fluphenazine. Acute dystonia, drug-induced parkinsonism, and akathisia all occur. Risk rises with higher doses. See our broader article on extrapyramidal symptoms.
Akathisia
Restlessness, especially in the legs and a need to keep moving. This is a common reason patients ask to switch off perphenazine. Lowering the dose, adding propranolol, or adding a low-dose benzodiazepine can help. Our akathisia guide walks through the options.
Tardive dyskinesia
Long-term cumulative risk of TD is similar to other first-generation drugs and higher than with most second-generation agents. Annual TD examinations using the AIMS scale are standard.
Metabolic and cardiovascular effects
Weight gain on perphenazine is generally modest — less than olanzapine or clozapine, comparable to risperidone in some studies. The risk of new-onset diabetes is lower than with olanzapine. Lipid effects are usually mild. Perphenazine can cause mild QT prolongation but less than thioridazine or droperidol.
Anticholinergic and sedative effects
Mid-potency drugs sit between the sedating, anticholinergic-heavy low-potency agents and the activating, EPS-prone high-potency ones. Patients on perphenazine sometimes experience dry mouth, mild constipation, and modest sedation, but these tend to be lighter than with chlorpromazine. Many people tolerate the daytime profile well.
Hyperprolactinemia
Like other D2 blockers, perphenazine raises prolactin levels. Symptoms include menstrual changes, galactorrhoea, sexual dysfunction, and over the long term, possible bone density effects. See our hyperprolactinemia article.
Less common but serious effects
- Neuroleptic malignant syndrome — rare, life-threatening; presents with fever, rigidity, confusion, autonomic instability. See our NMS overview.
- Seizures — perphenazine modestly lowers the seizure threshold; risk rises with rapid dose changes or in people with seizure disorders.
- Agranulocytosis — rare with perphenazine compared with clozapine, but cases have been reported.
- Hepatic effects — uncommon elevations in liver enzymes; clinically significant hepatitis is rare.
You develop high fever, severe muscle stiffness, confusion, or your heart is racing — these can signal NMS. Also seek care for new sustained involuntary movements of the face, tongue, or limbs.
Who tends to do well on perphenazine
- People who responded to it before
- People who are concerned about weight gain on second-generation drugs
- People who need an inexpensive option
- People who don't tolerate sedation from low-potency typicals
- People who find aripiprazole or other SGA options activating or dysphoric
Who might not
- People with prior bad EPS or current movement disorders
- Older adults at higher TD risk
- People with significant cardiac arrhythmia history
- People who are very sensitive to prolactin elevation
The big picture
Perphenazine is neither a miracle nor a relic. It is a serious medication with a balanced first-generation profile that, for the right patient, offers effective symptom control at a fraction of the cost of newer drugs. The CATIE trial reminded the field that "newer" does not automatically mean "better tolerated" — and that real-world effectiveness depends on a careful match between drug and person, monitored attentively over time. Whether perphenazine fits is a conversation to have with your prescriber, ideally with the trade-offs spelled out clearly.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.